nodes	percent_of_prediction	percent_of_DWPC	metapath
Pimecrolimus—CYP3A4—Efavirenz—acquired immunodeficiency syndrome	0.0671	0.126	CbGbCtD
Pimecrolimus—CYP3A4—Lopinavir—acquired immunodeficiency syndrome	0.0631	0.119	CbGbCtD
Pimecrolimus—CYP3A4—Nevirapine—acquired immunodeficiency syndrome	0.0631	0.119	CbGbCtD
Pimecrolimus—CYP3A4—Delavirdine—acquired immunodeficiency syndrome	0.057	0.107	CbGbCtD
Pimecrolimus—CYP3A4—Amprenavir—acquired immunodeficiency syndrome	0.057	0.107	CbGbCtD
Pimecrolimus—CYP3A4—Indinavir—acquired immunodeficiency syndrome	0.0492	0.0925	CbGbCtD
Pimecrolimus—CYP3A4—Nelfinavir—acquired immunodeficiency syndrome	0.0478	0.0898	CbGbCtD
Pimecrolimus—CYP3A4—Saquinavir—acquired immunodeficiency syndrome	0.0432	0.0812	CbGbCtD
Pimecrolimus—CYP3A4—Ritonavir—acquired immunodeficiency syndrome	0.0432	0.0812	CbGbCtD
Pimecrolimus—CYP3A4—Zidovudine—acquired immunodeficiency syndrome	0.0414	0.0779	CbGbCtD
Pimecrolimus—MTOR—blood plasma—acquired immunodeficiency syndrome	0.00842	0.0888	CbGeAlD
Pimecrolimus—FKBP1A—blood plasma—acquired immunodeficiency syndrome	0.00758	0.0799	CbGeAlD
Pimecrolimus—MTOR—retina—acquired immunodeficiency syndrome	0.00461	0.0486	CbGeAlD
Pimecrolimus—FKBP1A—retina—acquired immunodeficiency syndrome	0.00415	0.0437	CbGeAlD
Pimecrolimus—MTOR—skin of body—acquired immunodeficiency syndrome	0.00405	0.0427	CbGeAlD
Pimecrolimus—FKBP1A—skin of body—acquired immunodeficiency syndrome	0.00364	0.0384	CbGeAlD
Pimecrolimus—MTOR—lymphoid tissue—acquired immunodeficiency syndrome	0.00328	0.0346	CbGeAlD
Pimecrolimus—MTOR—digestive system—acquired immunodeficiency syndrome	0.00324	0.0341	CbGeAlD
Pimecrolimus—MTOR—blood—acquired immunodeficiency syndrome	0.00309	0.0325	CbGeAlD
Pimecrolimus—MTOR—bone marrow—acquired immunodeficiency syndrome	0.00299	0.0315	CbGeAlD
Pimecrolimus—MTOR—spinal cord—acquired immunodeficiency syndrome	0.00297	0.0313	CbGeAlD
Pimecrolimus—FKBP1A—lymphoid tissue—acquired immunodeficiency syndrome	0.00295	0.0311	CbGeAlD
Pimecrolimus—FKBP1A—digestive system—acquired immunodeficiency syndrome	0.00291	0.0307	CbGeAlD
Pimecrolimus—MTOR—vagina—acquired immunodeficiency syndrome	0.00286	0.0302	CbGeAlD
Pimecrolimus—FKBP1A—blood—acquired immunodeficiency syndrome	0.00278	0.0293	CbGeAlD
Pimecrolimus—MTOR—lung—acquired immunodeficiency syndrome	0.00271	0.0285	CbGeAlD
Pimecrolimus—FKBP1A—bone marrow—acquired immunodeficiency syndrome	0.00269	0.0283	CbGeAlD
Pimecrolimus—FKBP1A—spinal cord—acquired immunodeficiency syndrome	0.00267	0.0282	CbGeAlD
Pimecrolimus—FKBP1A—vagina—acquired immunodeficiency syndrome	0.00257	0.0271	CbGeAlD
Pimecrolimus—MTOR—nervous system—acquired immunodeficiency syndrome	0.00251	0.0264	CbGeAlD
Pimecrolimus—CYP3A4—blood plasma—acquired immunodeficiency syndrome	0.00248	0.0261	CbGeAlD
Pimecrolimus—FKBP1A—lung—acquired immunodeficiency syndrome	0.00243	0.0257	CbGeAlD
Pimecrolimus—MTOR—central nervous system—acquired immunodeficiency syndrome	0.00241	0.0254	CbGeAlD
Pimecrolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—CCNT1—acquired immunodeficiency syndrome	0.00226	0.0664	CbGpPWpGaD
Pimecrolimus—FKBP1A—nervous system—acquired immunodeficiency syndrome	0.00225	0.0238	CbGeAlD
Pimecrolimus—FKBP1A—central nervous system—acquired immunodeficiency syndrome	0.00217	0.0229	CbGeAlD
Pimecrolimus—MTOR—brain—acquired immunodeficiency syndrome	0.00191	0.0202	CbGeAlD
Pimecrolimus—MTOR—lymph node—acquired immunodeficiency syndrome	0.00185	0.0195	CbGeAlD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—acquired immunodeficiency syndrome	0.00182	0.0535	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CSF2—acquired immunodeficiency syndrome	0.0018	0.0529	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL4—acquired immunodeficiency syndrome	0.00177	0.052	CbGpPWpGaD
Pimecrolimus—FKBP1A—brain—acquired immunodeficiency syndrome	0.00172	0.0182	CbGeAlD
Pimecrolimus—FKBP1A—lymph node—acquired immunodeficiency syndrome	0.00166	0.0175	CbGeAlD
Pimecrolimus—MTOR—IL12-mediated signaling events—CCL4—acquired immunodeficiency syndrome	0.0013	0.0382	CbGpPWpGaD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IFNG—acquired immunodeficiency syndrome	0.00107	0.0314	CbGpPWpGaD
Pimecrolimus—CYP3A4—digestive system—acquired immunodeficiency syndrome	0.000952	0.01	CbGeAlD
Pimecrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—acquired immunodeficiency syndrome	0.000951	0.0279	CbGpPWpGaD
Pimecrolimus—CYP3A4—blood—acquired immunodeficiency syndrome	0.000907	0.00956	CbGeAlD
Pimecrolimus—MTOR—IL12-mediated signaling events—CCL3—acquired immunodeficiency syndrome	0.000888	0.0261	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—CCR2—acquired immunodeficiency syndrome	0.000831	0.0244	CbGpPWpGaD
Pimecrolimus—MTOR—Integrated Breast Cancer Pathway—APOBEC3G—acquired immunodeficiency syndrome	0.000807	0.0237	CbGpPWpGaD
Pimecrolimus—CYP3A4—nervous system—acquired immunodeficiency syndrome	0.000736	0.00776	CbGeAlD
Pimecrolimus—CYP3A4—central nervous system—acquired immunodeficiency syndrome	0.000709	0.00747	CbGeAlD
Pimecrolimus—Tacrolimus—ALB—acquired immunodeficiency syndrome	0.000653	1	CrCbGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—IFNG—acquired immunodeficiency syndrome	0.000651	0.0191	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CXCR4—acquired immunodeficiency syndrome	0.000577	0.0169	CbGpPWpGaD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CXCL12—acquired immunodeficiency syndrome	0.000577	0.0169	CbGpPWpGaD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL4—acquired immunodeficiency syndrome	0.000576	0.0169	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—CCL3—acquired immunodeficiency syndrome	0.000567	0.0167	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD8A—acquired immunodeficiency syndrome	0.000566	0.0166	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL10—acquired immunodeficiency syndrome	0.000557	0.0164	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—CD40LG—acquired immunodeficiency syndrome	0.000557	0.0164	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000556	0.0163	CbGpPWpGaD
Pimecrolimus—MTOR—IL4-mediated signaling events—IL4—acquired immunodeficiency syndrome	0.000542	0.0159	CbGpPWpGaD
Pimecrolimus—MTOR—IL12-mediated signaling events—CCR5—acquired immunodeficiency syndrome	0.000517	0.0152	CbGpPWpGaD
Pimecrolimus—MTOR—Type II diabetes mellitus—TNF—acquired immunodeficiency syndrome	0.000486	0.0143	CbGpPWpGaD
Pimecrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—acquired immunodeficiency syndrome	0.00044	0.0129	CbGpPWpGaD
Pimecrolimus—MTOR—IFN-gamma pathway—IFNG—acquired immunodeficiency syndrome	0.000439	0.0129	CbGpPWpGaD
Pimecrolimus—FKBP1A—TGF-beta Receptor Signaling—TNF—acquired immunodeficiency syndrome	0.000421	0.0124	CbGpPWpGaD
Pimecrolimus—Cough—Indinavir—acquired immunodeficiency syndrome	0.000407	0.0012	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Stavudine—acquired immunodeficiency syndrome	0.000406	0.0012	CcSEcCtD
Pimecrolimus—Immune system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000404	0.0012	CcSEcCtD
Pimecrolimus—Pain—Nelfinavir—acquired immunodeficiency syndrome	0.000404	0.00119	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000404	0.00119	CcSEcCtD
Pimecrolimus—Eye disorder—Saquinavir—acquired immunodeficiency syndrome	0.000403	0.00119	CcSEcCtD
Pimecrolimus—Constipation—Stavudine—acquired immunodeficiency syndrome	0.000403	0.00119	CcSEcCtD
Pimecrolimus—Pain—Stavudine—acquired immunodeficiency syndrome	0.000403	0.00119	CcSEcCtD
Pimecrolimus—Angioedema—Efavirenz—acquired immunodeficiency syndrome	0.000403	0.00119	CcSEcCtD
Pimecrolimus—Nervous system disorder—Zidovudine—acquired immunodeficiency syndrome	0.000401	0.00119	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Abacavir—acquired immunodeficiency syndrome	0.0004	0.00118	CcSEcCtD
Pimecrolimus—Hypersensitivity—Didanosine—acquired immunodeficiency syndrome	0.0004	0.00118	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Nevirapine—acquired immunodeficiency syndrome	0.000399	0.00118	CcSEcCtD
Pimecrolimus—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.000397	0.00118	CcSEcCtD
Pimecrolimus—Arthralgia—Indinavir—acquired immunodeficiency syndrome	0.000397	0.00117	CcSEcCtD
Pimecrolimus—Pain—Abacavir—acquired immunodeficiency syndrome	0.000397	0.00117	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Indinavir—acquired immunodeficiency syndrome	0.000394	0.00117	CcSEcCtD
Pimecrolimus—Malnutrition—Ritonavir—acquired immunodeficiency syndrome	0.00039	0.00115	CcSEcCtD
Pimecrolimus—Immune system disorder—Saquinavir—acquired immunodeficiency syndrome	0.000389	0.00115	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000388	0.00115	CcSEcCtD
Pimecrolimus—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.000387	0.00115	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000386	0.00114	CcSEcCtD
Pimecrolimus—Body temperature increased—Nevirapine—acquired immunodeficiency syndrome	0.000385	0.00114	CcSEcCtD
Pimecrolimus—Abdominal pain—Nevirapine—acquired immunodeficiency syndrome	0.000385	0.00114	CcSEcCtD
Pimecrolimus—Angioedema—Delavirdine—acquired immunodeficiency syndrome	0.000385	0.00114	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Stavudine—acquired immunodeficiency syndrome	0.000385	0.00114	CcSEcCtD
Pimecrolimus—Cough—Efavirenz—acquired immunodeficiency syndrome	0.000384	0.00114	CcSEcCtD
Pimecrolimus—Pruritus—Didanosine—acquired immunodeficiency syndrome	0.000384	0.00113	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Indinavir—acquired immunodeficiency syndrome	0.000381	0.00113	CcSEcCtD
Pimecrolimus—Oedema—Indinavir—acquired immunodeficiency syndrome	0.000381	0.00113	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Abacavir—acquired immunodeficiency syndrome	0.000379	0.00112	CcSEcCtD
Pimecrolimus—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.000378	0.00112	CcSEcCtD
Pimecrolimus—Back pain—Ritonavir—acquired immunodeficiency syndrome	0.000377	0.00111	CcSEcCtD
Pimecrolimus—Malnutrition—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.00111	CcSEcCtD
Pimecrolimus—Erythema—Saquinavir—acquired immunodeficiency syndrome	0.000375	0.00111	CcSEcCtD
Pimecrolimus—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.000375	0.00111	CcSEcCtD
Pimecrolimus—Arthralgia—Efavirenz—acquired immunodeficiency syndrome	0.000375	0.00111	CcSEcCtD
Pimecrolimus—Rash—Amprenavir—acquired immunodeficiency syndrome	0.000375	0.00111	CcSEcCtD
Pimecrolimus—Dermatitis—Amprenavir—acquired immunodeficiency syndrome	0.000375	0.00111	CcSEcCtD
Pimecrolimus—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.000374	0.00111	CcSEcCtD
Pimecrolimus—Abdominal pain—Nelfinavir—acquired immunodeficiency syndrome	0.000373	0.0011	CcSEcCtD
Pimecrolimus—Body temperature increased—Nelfinavir—acquired immunodeficiency syndrome	0.000373	0.0011	CcSEcCtD
Pimecrolimus—Nervous system disorder—Indinavir—acquired immunodeficiency syndrome	0.000373	0.0011	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Zidovudine—acquired immunodeficiency syndrome	0.000373	0.0011	CcSEcCtD
Pimecrolimus—Headache—Amprenavir—acquired immunodeficiency syndrome	0.000373	0.0011	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Efavirenz—acquired immunodeficiency syndrome	0.000372	0.0011	CcSEcCtD
Pimecrolimus—Body temperature increased—Stavudine—acquired immunodeficiency syndrome	0.000372	0.0011	CcSEcCtD
Pimecrolimus—Abdominal pain—Stavudine—acquired immunodeficiency syndrome	0.000372	0.0011	CcSEcCtD
Pimecrolimus—Immune system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000371	0.0011	CcSEcCtD
Pimecrolimus—Diarrhoea—Didanosine—acquired immunodeficiency syndrome	0.000371	0.0011	CcSEcCtD
Pimecrolimus—Mediastinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000371	0.0011	CcSEcCtD
Pimecrolimus—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00037	0.00109	CcSEcCtD
Pimecrolimus—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.000368	0.00109	CcSEcCtD
Pimecrolimus—Cough—Delavirdine—acquired immunodeficiency syndrome	0.000368	0.00109	CcSEcCtD
Pimecrolimus—Paraesthesia—Zidovudine—acquired immunodeficiency syndrome	0.000367	0.00109	CcSEcCtD
Pimecrolimus—Abdominal pain—Abacavir—acquired immunodeficiency syndrome	0.000367	0.00108	CcSEcCtD
Pimecrolimus—Body temperature increased—Abacavir—acquired immunodeficiency syndrome	0.000367	0.00108	CcSEcCtD
Pimecrolimus—Dyspnoea—Zidovudine—acquired immunodeficiency syndrome	0.000365	0.00108	CcSEcCtD
Pimecrolimus—Back pain—Saquinavir—acquired immunodeficiency syndrome	0.000363	0.00107	CcSEcCtD
Pimecrolimus—Hypersensitivity—Nevirapine—acquired immunodeficiency syndrome	0.000359	0.00106	CcSEcCtD
Pimecrolimus—Arthralgia—Delavirdine—acquired immunodeficiency syndrome	0.000359	0.00106	CcSEcCtD
Pimecrolimus—MTOR—Signaling by ERBB4—CXCL12—acquired immunodeficiency syndrome	0.000359	0.0105	CbGpPWpGaD
Pimecrolimus—Malnutrition—Lamivudine—acquired immunodeficiency syndrome	0.000358	0.00106	CcSEcCtD
Pimecrolimus—Erythema—Lamivudine—acquired immunodeficiency syndrome	0.000358	0.00106	CcSEcCtD
Pimecrolimus—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.000353	0.00104	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Zidovudine—acquired immunodeficiency syndrome	0.000353	0.00104	CcSEcCtD
Pimecrolimus—Nervous system disorder—Efavirenz—acquired immunodeficiency syndrome	0.000353	0.00104	CcSEcCtD
Pimecrolimus—Pain—Zidovudine—acquired immunodeficiency syndrome	0.00035	0.00103	CcSEcCtD
Pimecrolimus—Constipation—Zidovudine—acquired immunodeficiency syndrome	0.00035	0.00103	CcSEcCtD
Pimecrolimus—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.000349	0.00103	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IFNG—acquired immunodeficiency syndrome	0.000348	0.0102	CbGpPWpGaD
Pimecrolimus—Hypersensitivity—Nelfinavir—acquired immunodeficiency syndrome	0.000348	0.00103	CcSEcCtD
Pimecrolimus—Hypersensitivity—Stavudine—acquired immunodeficiency syndrome	0.000347	0.00103	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Indinavir—acquired immunodeficiency syndrome	0.000347	0.00103	CcSEcCtD
Pimecrolimus—Back pain—Lamivudine—acquired immunodeficiency syndrome	0.000346	0.00102	CcSEcCtD
Pimecrolimus—Pruritus—Nevirapine—acquired immunodeficiency syndrome	0.000345	0.00102	CcSEcCtD
Pimecrolimus—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.000345	0.00102	CcSEcCtD
Pimecrolimus—Oedema—Delavirdine—acquired immunodeficiency syndrome	0.000344	0.00102	CcSEcCtD
Pimecrolimus—Rash—Didanosine—acquired immunodeficiency syndrome	0.000342	0.00101	CcSEcCtD
Pimecrolimus—Infection—Delavirdine—acquired immunodeficiency syndrome	0.000342	0.00101	CcSEcCtD
Pimecrolimus—Paraesthesia—Indinavir—acquired immunodeficiency syndrome	0.000342	0.00101	CcSEcCtD
Pimecrolimus—Hypersensitivity—Abacavir—acquired immunodeficiency syndrome	0.000342	0.00101	CcSEcCtD
Pimecrolimus—Dermatitis—Didanosine—acquired immunodeficiency syndrome	0.000342	0.00101	CcSEcCtD
Pimecrolimus—Cough—Ritonavir—acquired immunodeficiency syndrome	0.00034	0.00101	CcSEcCtD
Pimecrolimus—Headache—Didanosine—acquired immunodeficiency syndrome	0.00034	0.001	CcSEcCtD
Pimecrolimus—Dyspnoea—Indinavir—acquired immunodeficiency syndrome	0.000339	0.001	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—IFNG—acquired immunodeficiency syndrome	0.000336	0.00988	CbGpPWpGaD
Pimecrolimus—Gastrointestinal pain—Zidovudine—acquired immunodeficiency syndrome	0.000335	0.000989	CcSEcCtD
Pimecrolimus—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.000334	0.000988	CcSEcCtD
Pimecrolimus—Pruritus—Nelfinavir—acquired immunodeficiency syndrome	0.000334	0.000988	CcSEcCtD
Pimecrolimus—Diarrhoea—Nevirapine—acquired immunodeficiency syndrome	0.000334	0.000986	CcSEcCtD
Pimecrolimus—Pruritus—Stavudine—acquired immunodeficiency syndrome	0.000333	0.000985	CcSEcCtD
Pimecrolimus—Arthralgia—Ritonavir—acquired immunodeficiency syndrome	0.000332	0.000981	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Ritonavir—acquired immunodeficiency syndrome	0.00033	0.000974	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Indinavir—acquired immunodeficiency syndrome	0.000329	0.000971	CcSEcCtD
Pimecrolimus—Pruritus—Abacavir—acquired immunodeficiency syndrome	0.000328	0.00097	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Efavirenz—acquired immunodeficiency syndrome	0.000328	0.000969	CcSEcCtD
Pimecrolimus—Cough—Saquinavir—acquired immunodeficiency syndrome	0.000327	0.000968	CcSEcCtD
Pimecrolimus—Angioedema—Lamivudine—acquired immunodeficiency syndrome	0.000327	0.000967	CcSEcCtD
Pimecrolimus—Pain—Indinavir—acquired immunodeficiency syndrome	0.000325	0.000962	CcSEcCtD
Pimecrolimus—Constipation—Indinavir—acquired immunodeficiency syndrome	0.000325	0.000962	CcSEcCtD
Pimecrolimus—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.000325	0.000961	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.000325	0.00954	CbGpPWpGaD
Pimecrolimus—Body temperature increased—Zidovudine—acquired immunodeficiency syndrome	0.000323	0.000956	CcSEcCtD
Pimecrolimus—Abdominal pain—Zidovudine—acquired immunodeficiency syndrome	0.000323	0.000956	CcSEcCtD
Pimecrolimus—Diarrhoea—Nelfinavir—acquired immunodeficiency syndrome	0.000323	0.000955	CcSEcCtD
Pimecrolimus—Paraesthesia—Efavirenz—acquired immunodeficiency syndrome	0.000323	0.000955	CcSEcCtD
Pimecrolimus—Diarrhoea—Stavudine—acquired immunodeficiency syndrome	0.000322	0.000952	CcSEcCtD
Pimecrolimus—Nausea—Didanosine—acquired immunodeficiency syndrome	0.000322	0.000952	CcSEcCtD
Pimecrolimus—Dyspnoea—Efavirenz—acquired immunodeficiency syndrome	0.000321	0.000948	CcSEcCtD
Pimecrolimus—Arthralgia—Saquinavir—acquired immunodeficiency syndrome	0.000319	0.000944	CcSEcCtD
Pimecrolimus—Oedema—Ritonavir—acquired immunodeficiency syndrome	0.000318	0.000941	CcSEcCtD
Pimecrolimus—Diarrhoea—Abacavir—acquired immunodeficiency syndrome	0.000317	0.000938	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Saquinavir—acquired immunodeficiency syndrome	0.000317	0.000938	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Delavirdine—acquired immunodeficiency syndrome	0.000313	0.000927	CcSEcCtD
Pimecrolimus—Cough—Lamivudine—acquired immunodeficiency syndrome	0.000312	0.000923	CcSEcCtD
Pimecrolimus—Nervous system disorder—Ritonavir—acquired immunodeficiency syndrome	0.000312	0.000922	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Indinavir—acquired immunodeficiency syndrome	0.000311	0.00092	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Efavirenz—acquired immunodeficiency syndrome	0.00031	0.000918	CcSEcCtD
Pimecrolimus—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.00031	0.000917	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL2—acquired immunodeficiency syndrome	0.000309	0.00909	CbGpPWpGaD
Pimecrolimus—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.000309	0.000914	CcSEcCtD
Pimecrolimus—Paraesthesia—Delavirdine—acquired immunodeficiency syndrome	0.000309	0.000913	CcSEcCtD
Pimecrolimus—Constipation—Efavirenz—acquired immunodeficiency syndrome	0.000307	0.000909	CcSEcCtD
Pimecrolimus—Pain—Efavirenz—acquired immunodeficiency syndrome	0.000307	0.000909	CcSEcCtD
Pimecrolimus—Rash—Nevirapine—acquired immunodeficiency syndrome	0.000307	0.000909	CcSEcCtD
Pimecrolimus—Dermatitis—Nevirapine—acquired immunodeficiency syndrome	0.000307	0.000908	CcSEcCtD
Pimecrolimus—Dyspnoea—Delavirdine—acquired immunodeficiency syndrome	0.000307	0.000907	CcSEcCtD
Pimecrolimus—Oedema—Saquinavir—acquired immunodeficiency syndrome	0.000306	0.000905	CcSEcCtD
Pimecrolimus—Headache—Nevirapine—acquired immunodeficiency syndrome	0.000305	0.000903	CcSEcCtD
Pimecrolimus—Arthralgia—Lamivudine—acquired immunodeficiency syndrome	0.000305	0.000901	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—IFNG—acquired immunodeficiency syndrome	0.000304	0.00894	CbGpPWpGaD
Pimecrolimus—Infection—Saquinavir—acquired immunodeficiency syndrome	0.000304	0.000899	CcSEcCtD
Pimecrolimus—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—acquired immunodeficiency syndrome	0.000303	0.000895	CcSEcCtD
Pimecrolimus—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.000302	0.000894	CcSEcCtD
Pimecrolimus—Abdominal pain—Indinavir—acquired immunodeficiency syndrome	0.000301	0.00089	CcSEcCtD
Pimecrolimus—Body temperature increased—Indinavir—acquired immunodeficiency syndrome	0.000301	0.00089	CcSEcCtD
Pimecrolimus—Nervous system disorder—Saquinavir—acquired immunodeficiency syndrome	0.0003	0.000888	CcSEcCtD
Pimecrolimus—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.0003	0.000888	CcSEcCtD
Pimecrolimus—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.000299	0.000885	CcSEcCtD
Pimecrolimus—MTOR—IL12-mediated signaling events—IL2—acquired immunodeficiency syndrome	0.000299	0.00878	CbGpPWpGaD
Pimecrolimus—Rash—Nelfinavir—acquired immunodeficiency syndrome	0.000298	0.00088	CcSEcCtD
Pimecrolimus—Dermatitis—Nelfinavir—acquired immunodeficiency syndrome	0.000297	0.00088	CcSEcCtD
Pimecrolimus—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.000297	0.000879	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Delavirdine—acquired immunodeficiency syndrome	0.000297	0.000878	CcSEcCtD
Pimecrolimus—Rash—Stavudine—acquired immunodeficiency syndrome	0.000297	0.000878	CcSEcCtD
Pimecrolimus—Dermatitis—Stavudine—acquired immunodeficiency syndrome	0.000297	0.000877	CcSEcCtD
Pimecrolimus—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.000296	0.000875	CcSEcCtD
Pimecrolimus—Headache—Stavudine—acquired immunodeficiency syndrome	0.000295	0.000872	CcSEcCtD
Pimecrolimus—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.000295	0.000872	CcSEcCtD
Pimecrolimus—Pain—Delavirdine—acquired immunodeficiency syndrome	0.000294	0.00087	CcSEcCtD
Pimecrolimus—Constipation—Delavirdine—acquired immunodeficiency syndrome	0.000294	0.00087	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Efavirenz—acquired immunodeficiency syndrome	0.000294	0.000869	CcSEcCtD
Pimecrolimus—MTOR—Costimulation by the CD28 family—CD4—acquired immunodeficiency syndrome	0.000294	0.00863	CbGpPWpGaD
Pimecrolimus—Rash—Abacavir—acquired immunodeficiency syndrome	0.000292	0.000865	CcSEcCtD
Pimecrolimus—Dermatitis—Abacavir—acquired immunodeficiency syndrome	0.000292	0.000864	CcSEcCtD
Pimecrolimus—Oedema—Lamivudine—acquired immunodeficiency syndrome	0.000292	0.000864	CcSEcCtD
Pimecrolimus—Anaphylactic shock—Lamivudine—acquired immunodeficiency syndrome	0.000292	0.000864	CcSEcCtD
Pimecrolimus—Headache—Abacavir—acquired immunodeficiency syndrome	0.000291	0.000859	CcSEcCtD
Pimecrolimus—Infection—Lamivudine—acquired immunodeficiency syndrome	0.00029	0.000858	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Ritonavir—acquired immunodeficiency syndrome	0.00029	0.000857	CcSEcCtD
Pimecrolimus—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00029	0.000856	CcSEcCtD
Pimecrolimus—Pruritus—Zidovudine—acquired immunodeficiency syndrome	0.00029	0.000856	CcSEcCtD
Pimecrolimus—Nervous system disorder—Lamivudine—acquired immunodeficiency syndrome	0.000286	0.000847	CcSEcCtD
Pimecrolimus—Paraesthesia—Ritonavir—acquired immunodeficiency syndrome	0.000286	0.000845	CcSEcCtD
Pimecrolimus—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.000286	0.000845	CcSEcCtD
Pimecrolimus—Body temperature increased—Efavirenz—acquired immunodeficiency syndrome	0.000284	0.00084	CcSEcCtD
Pimecrolimus—Abdominal pain—Efavirenz—acquired immunodeficiency syndrome	0.000284	0.00084	CcSEcCtD
Pimecrolimus—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.000284	0.000839	CcSEcCtD
Pimecrolimus—Dyspnoea—Ritonavir—acquired immunodeficiency syndrome	0.000284	0.000839	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Delavirdine—acquired immunodeficiency syndrome	0.000281	0.000832	CcSEcCtD
Pimecrolimus—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.000281	0.000829	CcSEcCtD
Pimecrolimus—Hypersensitivity—Indinavir—acquired immunodeficiency syndrome	0.00028	0.000829	CcSEcCtD
Pimecrolimus—Diarrhoea—Zidovudine—acquired immunodeficiency syndrome	0.00028	0.000828	CcSEcCtD
Pimecrolimus—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00028	0.000827	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Saquinavir—acquired immunodeficiency syndrome	0.000279	0.000825	CcSEcCtD
Pimecrolimus—Nausea—Abacavir—acquired immunodeficiency syndrome	0.000275	0.000815	CcSEcCtD
Pimecrolimus—Paraesthesia—Saquinavir—acquired immunodeficiency syndrome	0.000275	0.000813	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Ritonavir—acquired immunodeficiency syndrome	0.000275	0.000812	CcSEcCtD
Pimecrolimus—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.000273	0.000808	CcSEcCtD
Pimecrolimus—MTOR—B Cell Activation—CD79A—acquired immunodeficiency syndrome	0.000273	0.00803	CbGpPWpGaD
Pimecrolimus—Dyspnoea—Saquinavir—acquired immunodeficiency syndrome	0.000273	0.000807	CcSEcCtD
Pimecrolimus—Pain—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.000804	CcSEcCtD
Pimecrolimus—Constipation—Ritonavir—acquired immunodeficiency syndrome	0.000272	0.000804	CcSEcCtD
Pimecrolimus—Abdominal pain—Delavirdine—acquired immunodeficiency syndrome	0.000272	0.000804	CcSEcCtD
Pimecrolimus—Body temperature increased—Delavirdine—acquired immunodeficiency syndrome	0.000272	0.000804	CcSEcCtD
Pimecrolimus—MTOR—Regulation of Telomerase—IL2—acquired immunodeficiency syndrome	0.00027	0.00794	CbGpPWpGaD
Pimecrolimus—Pruritus—Indinavir—acquired immunodeficiency syndrome	0.000269	0.000796	CcSEcCtD
Pimecrolimus—Musculoskeletal discomfort—Lamivudine—acquired immunodeficiency syndrome	0.000266	0.000787	CcSEcCtD
Pimecrolimus—Hypersensitivity—Efavirenz—acquired immunodeficiency syndrome	0.000265	0.000783	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Saquinavir—acquired immunodeficiency syndrome	0.000264	0.000782	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000264	0.00776	CbGpPWpGaD
Pimecrolimus—Paraesthesia—Lamivudine—acquired immunodeficiency syndrome	0.000262	0.000776	CcSEcCtD
Pimecrolimus—Pain—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.000774	CcSEcCtD
Pimecrolimus—Constipation—Saquinavir—acquired immunodeficiency syndrome	0.000262	0.000774	CcSEcCtD
Pimecrolimus—Dyspnoea—Lamivudine—acquired immunodeficiency syndrome	0.00026	0.00077	CcSEcCtD
Pimecrolimus—Diarrhoea—Indinavir—acquired immunodeficiency syndrome	0.00026	0.00077	CcSEcCtD
Pimecrolimus—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00026	0.000769	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Ritonavir—acquired immunodeficiency syndrome	0.00026	0.000769	CcSEcCtD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.00026	0.00763	CbGpPWpGaD
Pimecrolimus—Rash—Zidovudine—acquired immunodeficiency syndrome	0.000258	0.000763	CcSEcCtD
Pimecrolimus—Dermatitis—Zidovudine—acquired immunodeficiency syndrome	0.000258	0.000762	CcSEcCtD
Pimecrolimus—Headache—Zidovudine—acquired immunodeficiency syndrome	0.000256	0.000758	CcSEcCtD
Pimecrolimus—Pruritus—Efavirenz—acquired immunodeficiency syndrome	0.000254	0.000752	CcSEcCtD
Pimecrolimus—Hypersensitivity—Delavirdine—acquired immunodeficiency syndrome	0.000253	0.000749	CcSEcCtD
Pimecrolimus—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.000253	0.000747	CcSEcCtD
Pimecrolimus—Gastrointestinal disorder—Lamivudine—acquired immunodeficiency syndrome	0.000252	0.000746	CcSEcCtD
Pimecrolimus—Body temperature increased—Ritonavir—acquired immunodeficiency syndrome	0.000251	0.000744	CcSEcCtD
Pimecrolimus—Abdominal pain—Ritonavir—acquired immunodeficiency syndrome	0.000251	0.000744	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Saquinavir—acquired immunodeficiency syndrome	0.00025	0.00074	CcSEcCtD
Pimecrolimus—Constipation—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.000739	CcSEcCtD
Pimecrolimus—Pain—Lamivudine—acquired immunodeficiency syndrome	0.00025	0.000739	CcSEcCtD
Pimecrolimus—MTOR—CXCR4-mediated signaling events—CD4—acquired immunodeficiency syndrome	0.000248	0.00729	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Efavirenz—acquired immunodeficiency syndrome	0.000246	0.000727	CcSEcCtD
Pimecrolimus—Pruritus—Delavirdine—acquired immunodeficiency syndrome	0.000243	0.00072	CcSEcCtD
Pimecrolimus—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.000243	0.000719	CcSEcCtD
Pimecrolimus—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.000243	0.000719	CcSEcCtD
Pimecrolimus—Abdominal pain—Saquinavir—acquired immunodeficiency syndrome	0.000242	0.000716	CcSEcCtD
Pimecrolimus—Body temperature increased—Saquinavir—acquired immunodeficiency syndrome	0.000242	0.000716	CcSEcCtD
Pimecrolimus—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.000242	0.000715	CcSEcCtD
Pimecrolimus—Rash—Indinavir—acquired immunodeficiency syndrome	0.00024	0.000709	CcSEcCtD
Pimecrolimus—Dermatitis—Indinavir—acquired immunodeficiency syndrome	0.00024	0.000709	CcSEcCtD
Pimecrolimus—Gastrointestinal pain—Lamivudine—acquired immunodeficiency syndrome	0.000239	0.000706	CcSEcCtD
Pimecrolimus—Headache—Indinavir—acquired immunodeficiency syndrome	0.000238	0.000705	CcSEcCtD
Pimecrolimus—Diarrhoea—Delavirdine—acquired immunodeficiency syndrome	0.000235	0.000696	CcSEcCtD
Pimecrolimus—Hypersensitivity—Ritonavir—acquired immunodeficiency syndrome	0.000234	0.000693	CcSEcCtD
Pimecrolimus—MTOR—Cardiac Hypertrophic Response—TNF—acquired immunodeficiency syndrome	0.000233	0.00686	CbGpPWpGaD
Pimecrolimus—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.000232	0.000686	CcSEcCtD
Pimecrolimus—Abdominal pain—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000683	CcSEcCtD
Pimecrolimus—Body temperature increased—Lamivudine—acquired immunodeficiency syndrome	0.000231	0.000683	CcSEcCtD
Pimecrolimus—MTOR—DAP12 interactions—HLA-B—acquired immunodeficiency syndrome	0.000229	0.00673	CbGpPWpGaD
Pimecrolimus—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.000229	0.000676	CcSEcCtD
Pimecrolimus—Rash—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.00067	CcSEcCtD
Pimecrolimus—Dermatitis—Efavirenz—acquired immunodeficiency syndrome	0.000227	0.00067	CcSEcCtD
Pimecrolimus—Nausea—Indinavir—acquired immunodeficiency syndrome	0.000226	0.000668	CcSEcCtD
Pimecrolimus—Hypersensitivity—Saquinavir—acquired immunodeficiency syndrome	0.000226	0.000667	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—TNF—acquired immunodeficiency syndrome	0.000225	0.00662	CbGpPWpGaD
Pimecrolimus—Headache—Efavirenz—acquired immunodeficiency syndrome	0.000225	0.000666	CcSEcCtD
Pimecrolimus—Pruritus—Ritonavir—acquired immunodeficiency syndrome	0.000225	0.000666	CcSEcCtD
Pimecrolimus—FKBP1A—Disease—CCNT1—acquired immunodeficiency syndrome	0.000225	0.0066	CbGpPWpGaD
Pimecrolimus—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.000219	0.000647	CcSEcCtD
Pimecrolimus—Diarrhoea—Ritonavir—acquired immunodeficiency syndrome	0.000218	0.000644	CcSEcCtD
Pimecrolimus—Rash—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.000641	CcSEcCtD
Pimecrolimus—Dermatitis—Delavirdine—acquired immunodeficiency syndrome	0.000217	0.000641	CcSEcCtD
Pimecrolimus—Pruritus—Saquinavir—acquired immunodeficiency syndrome	0.000217	0.000641	CcSEcCtD
Pimecrolimus—Headache—Delavirdine—acquired immunodeficiency syndrome	0.000216	0.000637	CcSEcCtD
Pimecrolimus—Hypersensitivity—Lamivudine—acquired immunodeficiency syndrome	0.000215	0.000636	CcSEcCtD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IFNG—acquired immunodeficiency syndrome	0.000215	0.00632	CbGpPWpGaD
Pimecrolimus—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.000214	0.000631	CcSEcCtD
Pimecrolimus—MTOR—TSLP Signaling Pathway—IL6—acquired immunodeficiency syndrome	0.000214	0.00628	CbGpPWpGaD
Pimecrolimus—Diarrhoea—Saquinavir—acquired immunodeficiency syndrome	0.00021	0.000619	CcSEcCtD
Pimecrolimus—Pruritus—Lamivudine—acquired immunodeficiency syndrome	0.000207	0.000611	CcSEcCtD
Pimecrolimus—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.000204	0.000604	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—ACTG1—acquired immunodeficiency syndrome	0.000204	0.00599	CbGpPWpGaD
Pimecrolimus—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.000202	0.000598	CcSEcCtD
Pimecrolimus—Rash—Ritonavir—acquired immunodeficiency syndrome	0.000201	0.000593	CcSEcCtD
Pimecrolimus—Dermatitis—Ritonavir—acquired immunodeficiency syndrome	0.0002	0.000593	CcSEcCtD
Pimecrolimus—Diarrhoea—Lamivudine—acquired immunodeficiency syndrome	0.0002	0.000591	CcSEcCtD
Pimecrolimus—Headache—Ritonavir—acquired immunodeficiency syndrome	0.000199	0.000589	CcSEcCtD
Pimecrolimus—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.000195	0.000576	CcSEcCtD
Pimecrolimus—Rash—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.000571	CcSEcCtD
Pimecrolimus—Dermatitis—Saquinavir—acquired immunodeficiency syndrome	0.000193	0.00057	CcSEcCtD
Pimecrolimus—Headache—Saquinavir—acquired immunodeficiency syndrome	0.000192	0.000567	CcSEcCtD
Pimecrolimus—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.000189	0.000559	CcSEcCtD
Pimecrolimus—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.000186	0.000549	CcSEcCtD
Pimecrolimus—Rash—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000545	CcSEcCtD
Pimecrolimus—Dermatitis—Lamivudine—acquired immunodeficiency syndrome	0.000184	0.000544	CcSEcCtD
Pimecrolimus—Headache—Lamivudine—acquired immunodeficiency syndrome	0.000183	0.000541	CcSEcCtD
Pimecrolimus—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.000182	0.000538	CcSEcCtD
Pimecrolimus—FKBP1A—Spinal Cord Injury—IL6—acquired immunodeficiency syndrome	0.000182	0.00534	CbGpPWpGaD
Pimecrolimus—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.000174	0.000513	CcSEcCtD
Pimecrolimus—MTOR—Innate Immune System—MBL2—acquired immunodeficiency syndrome	0.000167	0.00492	CbGpPWpGaD
Pimecrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TNF—acquired immunodeficiency syndrome	0.000166	0.00489	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000157	0.00462	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000157	0.00462	CbGpPWpGaD
Pimecrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TNF—acquired immunodeficiency syndrome	0.000153	0.0045	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—APOBEC3G—acquired immunodeficiency syndrome	0.000149	0.00437	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000146	0.00429	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000142	0.00418	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-mediated signalling—IL6—acquired immunodeficiency syndrome	0.000133	0.00391	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CCR2—acquired immunodeficiency syndrome	0.000131	0.00386	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events—IL6—acquired immunodeficiency syndrome	0.000129	0.0038	CbGpPWpGaD
Pimecrolimus—MTOR—IRS-related events triggered by IGF1R—IL6—acquired immunodeficiency syndrome	0.000128	0.00377	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCNT1—acquired immunodeficiency syndrome	0.000126	0.00371	CbGpPWpGaD
Pimecrolimus—MTOR—IGF1R signaling cascade—IL6—acquired immunodeficiency syndrome	0.000125	0.00367	CbGpPWpGaD
Pimecrolimus—MTOR—Insulin receptor signalling cascade—IL6—acquired immunodeficiency syndrome	0.000125	0.00367	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—ACTG1—acquired immunodeficiency syndrome	0.000119	0.00349	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IFNA1—acquired immunodeficiency syndrome	0.000118	0.00347	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CXCR4—acquired immunodeficiency syndrome	0.000118	0.00347	CbGpPWpGaD
Pimecrolimus—MTOR—Senescence and Autophagy in Cancer—IL6—acquired immunodeficiency syndrome	0.000112	0.0033	CbGpPWpGaD
Pimecrolimus—MTOR—VEGFA-VEGFR2 Pathway—IL6—acquired immunodeficiency syndrome	0.000111	0.00325	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD79A—acquired immunodeficiency syndrome	0.00011	0.00324	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by VEGF—IL6—acquired immunodeficiency syndrome	0.000104	0.00307	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by Insulin receptor—IL6—acquired immunodeficiency syndrome	0.000104	0.00305	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—MBL2—acquired immunodeficiency syndrome	9.75e-05	0.00286	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	9.72e-05	0.00286	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD40LG—acquired immunodeficiency syndrome	8.98e-05	0.00264	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—HLA-B—acquired immunodeficiency syndrome	8.9e-05	0.00261	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD8A—acquired immunodeficiency syndrome	8.88e-05	0.00261	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by SCF-KIT—IL6—acquired immunodeficiency syndrome	8.87e-05	0.00261	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	8.85e-05	0.0026	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	8.85e-05	0.0026	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	8.79e-05	0.00258	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—HLA-B—acquired immunodeficiency syndrome	8.54e-05	0.00251	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signaling of activated FGFR—IL6—acquired immunodeficiency syndrome	8.49e-05	0.00249	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB4—IL6—acquired immunodeficiency syndrome	8.35e-05	0.00245	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.26e-05	0.00243	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.26e-05	0.00243	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CCR5—acquired immunodeficiency syndrome	8.09e-05	0.00238	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	8e-05	0.00235	CbGpPWpGaD
Pimecrolimus—MTOR—Downstream signal transduction—IL6—acquired immunodeficiency syndrome	7.98e-05	0.00234	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR—IL6—acquired immunodeficiency syndrome	7.94e-05	0.00233	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by ERBB2—IL6—acquired immunodeficiency syndrome	7.9e-05	0.00232	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 signaling—IL6—acquired immunodeficiency syndrome	7.86e-05	0.00231	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CCR2—acquired immunodeficiency syndrome	7.65e-05	0.00225	CbGpPWpGaD
Pimecrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—IL6—acquired immunodeficiency syndrome	7.39e-05	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by FGFR in disease—IL6—acquired immunodeficiency syndrome	7.39e-05	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—DAP12 interactions—IL6—acquired immunodeficiency syndrome	7.39e-05	0.00217	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR—IL6—acquired immunodeficiency syndrome	7.33e-05	0.00215	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by EGFR in Cancer—IL6—acquired immunodeficiency syndrome	7.26e-05	0.00213	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by PDGF—IL6—acquired immunodeficiency syndrome	7.23e-05	0.00212	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNA1—acquired immunodeficiency syndrome	6.88e-05	0.00202	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD79A—acquired immunodeficiency syndrome	6.68e-05	0.00196	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CXCR4—acquired immunodeficiency syndrome	6.64e-05	0.00195	CbGpPWpGaD
Pimecrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—IL6—acquired immunodeficiency syndrome	6.55e-05	0.00192	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.29e-05	0.00185	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.19e-05	0.00182	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	5.66e-05	0.00166	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	5.47e-05	0.00161	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD40LG—acquired immunodeficiency syndrome	5.45e-05	0.0016	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD8A—acquired immunodeficiency syndrome	5.39e-05	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CSF2—acquired immunodeficiency syndrome	5.39e-05	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Cellular responses to stress—IL6—acquired immunodeficiency syndrome	5.37e-05	0.00158	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—CD4—acquired immunodeficiency syndrome	5.31e-05	0.00156	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—HLA-B—acquired immunodeficiency syndrome	5.18e-05	0.00152	CbGpPWpGaD
Pimecrolimus—MTOR—Adaptive Immune System—CD4—acquired immunodeficiency syndrome	5.1e-05	0.0015	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—CD4—acquired immunodeficiency syndrome	5.08e-05	0.00149	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling by NGF—IL6—acquired immunodeficiency syndrome	5.04e-05	0.00148	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	4.94e-05	0.00145	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	4.65e-05	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	4.65e-05	0.00137	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CCR5—acquired immunodeficiency syndrome	4.55e-05	0.00134	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—TAT—acquired immunodeficiency syndrome	4.13e-05	0.00121	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	3.54e-05	0.00104	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—AGPS—acquired immunodeficiency syndrome	3.51e-05	0.00103	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	3.48e-05	0.00102	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.27e-05	0.000961	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IFNG—acquired immunodeficiency syndrome	3.2e-05	0.000941	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	3.19e-05	0.000936	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—CD4—acquired immunodeficiency syndrome	3.09e-05	0.000909	CbGpPWpGaD
Pimecrolimus—MTOR—Innate Immune System—IL6—acquired immunodeficiency syndrome	2.87e-05	0.000844	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—CD4—acquired immunodeficiency syndrome	2.86e-05	0.000839	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL2—acquired immunodeficiency syndrome	2.85e-05	0.000836	CbGpPWpGaD
Pimecrolimus—FKBP1A—Disease—IL6—acquired immunodeficiency syndrome	2.75e-05	0.000807	CbGpPWpGaD
Pimecrolimus—FKBP1A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.92e-05	0.000565	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL2—acquired immunodeficiency syndrome	1.84e-05	0.000541	CbGpPWpGaD
Pimecrolimus—MTOR—Immune System—IL6—acquired immunodeficiency syndrome	1.67e-05	0.000492	CbGpPWpGaD
Pimecrolimus—MTOR—Disease—IL6—acquired immunodeficiency syndrome	1.54e-05	0.000454	CbGpPWpGaD
Pimecrolimus—MTOR—Signaling Pathways—IL6—acquired immunodeficiency syndrome	1.08e-05	0.000318	CbGpPWpGaD
Pimecrolimus—CYP3A4—Metabolism—ALB—acquired immunodeficiency syndrome	7.2e-06	0.000212	CbGpPWpGaD
